Mechanisms for control of skin immune function by the microbiome

The skin represents the largest area for direct contact between microbes and host immunocytes and is a site for constant communication between the host and this diverse and essential microbial community. Coagulase-negative staphylococci are an abundant bacterial genus on the human skin and are regul...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in immunology 2021-10, Vol.72, p.324-330
Main Authors: Nakatsuji, Teruaki, Cheng, Joyce Y, Gallo, Richard L
Format: Article
Language:English
Subjects:
Animals
Biomarkers
Disease Management
Disease Susceptibility
Dysbiosis
Host Microbial Interactions - immunology
Humans
Immunomodulation
Microbial Interactions - immunology
Microbiota - immunology
Skin - immunology
Skin - microbiology
Skin Physiological Phenomena
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The skin represents the largest area for direct contact between microbes and host immunocytes and is a site for constant communication between the host and this diverse and essential microbial community. Coagulase-negative staphylococci are an abundant bacterial genus on the human skin and are regulated through various mechanisms that include the epidermal barrier environment and innate and adaptive immune systems within the epidermis and dermis. In turn, some species and strains of these bacteria produce beneficial products that augment host immunity by exerting specifically targeted antimicrobial, anti-inflammatory, or anti-neoplastic activity while also promoting broad innate and adaptive immune responses. The use of selected skin commensals as a therapeutic has shown promise in recent human clinical trials. This emerging concept of bacteriotherapy is defining mechanisms of action and validating the dependence on the microbiome for maintenance of immune homeostasis.
ISSN:0952-7915
1879-0372
DOI:10.1016/j.coi.2021.09.001